SAM
XENE icon

Smartleaf Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Smartleaf Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$667 Sell
12
-4
-25% -$184 ﹤0.01% 3179
2025
Q4 		$706 Buy
+16
New +$672 ﹤0.01% 3221

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Smartleaf Asset Management's XENE Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 25% in Q1 2026, selling an estimated $184 and leaving 12 shares worth $667. The position accounts for ﹤0.01% of the portfolio, ranked #3179.

Smartleaf Asset Management first reported a position in XENE in Q4 2025 and has held it in 2 quarters since. The position peaked at $706 in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Smartleaf Asset Management held 12 shares of Xenon Pharmaceuticals worth $667 as of Q1 2026.
  • Smartleaf Asset Management sold 4 Xenon Pharmaceuticals shares in Q1 2026, an estimated $184.
  • Xenon Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3179 holding.
  • Smartleaf Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Smartleaf Asset Management's Xenon Pharmaceuticals position peaked at $706 in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.